Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918357 · ClinicalTrials.gov registry record · Phase 2
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
NCT02918357 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 385 participants.
The verdict
NCT02918357, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
Study Summary
The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.
Interventions
- DRUG Ga-68 labeled PSMA-11 PET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2016-09-15 |
| Est. Completion | 2017-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02918357
The ClinicalTrials.gov registry entry for NCT02918357 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ga-68 labeled PSMA-11 PET is the first listed.
NCT02918357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02918357 about?
NCT02918357 is a clinical study titled "Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence". The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate it's ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.
What is the current status of trial NCT02918357?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2016-09-15. Estimated completion is 2017-09-21.
What interventions are being tested in trial NCT02918357?
The interventions under investigation include: Ga-68 labeled PSMA-11 PET (DRUG).
Who is sponsoring clinical trial NCT02918357?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.